November 9, 2012
The US FDA announced on November 6 that it has approved Pfizer Inc.’s novel rheumatoid arthritis (RA) treatment Janus kinase (JAK) inhibitor tofacitinib (brand name: Xeljanz). Tofacitinib, a small molecular oral agent, is not only the first disease-modifying antirheumatic drug...read more